Gastric and Colon Metastasis From Breast Cancer: Case Report, Review of the Literature, and Possible Underlying Mechanisms
[Breast Cancer: Targets and Therapy] This research presents a case report of patient with gastrointestinal metastases from breast cancer.
Although significant variation in care persists, underuse and misuse of adjuvant endocrine therapy for breast cancer has decreased since 2004.
Administering chemotherapy to African-American women with breast cancer prior to surgery may help improve their survival.
Researchers report that clinicians may want to start collecting toxicity data routinely and offering early interventions to patients with breast cancer.
Letrozole was not superior to anastrazole with respect to efficacy or safety in postmenopausal women with HR-positive, node-positive early breast cancer.
Researchers sought to determine the noninferiority of continuing zoledronic acid for an additional year every 12 weeks vs zoledronic acid every 4 weeks in patients receiving monthly intravenous zoledronic acid and/or pamidronate disodium for 1 year or longer.
New Understanding of Mechanisms Revealed in Development of Breast Cancer and Resistance to Treatment
Researchers explore the biologic influences of breast cancer development and resistance to treatment.
In this study, researchers quantified the frequency, severity, and burden of treatment-associated toxicities in patients with early-stage invasive breast cancer using patient surveys.
CDK 4/6 inhibitors, currently approved for the treatment of estrogen-positive breast cancer, were found to inhibit metastasis in triple-negative breast
The Attention and Interpretation Modification for Fear of Breast Cancer Recurrence (AIM-FBCR) intervention helped reduce health worries for survivors of breast cancer.
An assessment of the use of mammography and colonoscopy among fee-for-service Medicare beneficiaries before and after the Affordable Care Act demonstrates the impact of out-of-pocket costs in this population.
A review of data from 2 Danish cancer registries revealed the incidence of overdiagnosis of tumors not likely to affect a patient's health during her lifetime and diagnosis of advanced tumors in a program offering biennial mammography for women aged 50 to 69 years.
A cohort of participants in the MAP.3 trial completed the MENQOL questionnaire, and the findings shed light on the influence of changes in menopause-specific quality of life on aromatase inhibitor adherence in women at high risk for breast cancer.
Features mainly linked to mammographic breast density are key in influencing a classification of normal.
Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.
In this study, researchers sought to identify physical, neurocognitive, and serologic markers that may correlate with self-reported fatigue before and after (neo)adjuvant chemotherapy for patients with early-stage breast cancer.
Researchers sought to evaluate the incidence of cancer-related cognitive impairment in patients with breast cancer in a large prospective, longitudinal, nationwide study. These findings address limitations in previous research.
Drug-drug interaction between capecitabine and common heartburn medications has a negative effect on progression-free survival and overall survival in patients with GI cancer.
Women with a history of breast cancer face a wide variety of challenges as they transition from the role of "patient" to "survivor".
Investigators have identified a genetic biomarker that can help determine congestive heart failure risk in individuals undergoing chemotherapy for breast cancer.
More women tested for the BRCA genes but no corresponding increase in mastectomy rates
Participants in a peer navigation program for patients at risk for HBOC were surveyed regarding the usefulness of the information provided, patient education, and their peer navigator. Survey results were presented at the 2016 SABCS.
An app developed to track posthospitalization progress and activity of patients with breast cancer, adding the information into patients' electronic health records in real time, was presented at SABCS 2016.
Weak social ties are associated with poorer survival and a higher risk of breast cancer recurrence, researchers say.
A new system appears efficacious in preventing chemotherapy-related alopecia in women with breast cancer, according to a study presented at SABCS 2016.
Women who experienced menopause-related side effects were significantly less likely to adhere to their assigned tamoxifen therapy.
Community Breast Navigation Program Improved Breast Screening Rates in Underserved African American and Latino Women
A community breast navigation program successfully increased mammogram screening rates among African American and Latino women, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
Live-streamed videos are a novel and forward-thinking approach for individuals to learn about end-of-life (EOL) planning and decision-making, according a study presented at the 2016 San Antonio Breast Cancer Symposium.
Patients with metastatic breast cancer have significantly diminished quality of life (QoL) compared with those without metastatic disease and those without breast cancer, a study presented at the 2016 San Antonio Breast Cancer Symposium.
History of Bilateral Salpingo-oophorectomy, Hormone Replacement Therapy Are Predictive of Breast Density at Cancer Diagnosis
A history of surgical menopause and were receiving hormone replacement therapy are a factor in breast density, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
Study data presented at SABCS 2016 indicates that preoperative MRI is effective for detecting mammographically occult, early-stage, hormone receptor (HR)-positive contralateral breast cancer (CBC) in older patients.
Clinical breast examination (CBE) is superior to MRI for predicting pathologic complete response (pCR) in women with HER2-positive breast cancer, a study presented at the 2016 San Antonio Breast Cancer Symposium indicates.
A new tool may show promise for improving clinical trial participation among black women with breast cancer, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
Research presented at SABCS 2016 identified biomarkers predictive of response to trastuzumab-containing therapies in patients with HER2-positive breast cancer.
Results of a comparison study of radioactive seed localization and wire guided localization in patients with nonpalpable invasive breast cancer or DCIS were presented at SABCS 2016.
A novel bromodomain-containing protein 4 inhibitor demonstrated antitumor activity in both endocrine-sensitive and endocrine-resistance breast cancer models, according to a study presented at SABCS 2016.
Patients with HER2-positive, HR-positive advanced breast cancer experience significantly improved progression-free survival when pertuzumab is added to first-line trastuzumab and an AI compared with trastuzumab and an AI alone, according to study findings presented at SABCS 2016.
Investigators report on the efficacy of a structured prophylactic regimen of loperamide for 2 cycles to reduce incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer, at SABCS 2016.
In this presentation at SABCS 2016, researchers present an evaluation of the ability of the PAM50 HER2-enriched intrinsic subtype to predict pathologic complete response in the breast in patients who received 18 weeks of neoadjuvant dual HER2 blockade.
Researchers found that temporary pretreatment with LDA may protect normal breast tissue during chemotherapy for breast cancer in patients undergoing breast-conserving therapy, according to a study presented at SABCS 2016.
In a poster presentation at SABCS 2016, researchers reported on the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of CINV in patients receiving highly or moderately emetogenic chemotherapy.
A study presented at SABCS 2016 reports on the incidence of complications and costs in women who undergo breast-conserving surgery for breast carcinoma.
Researchers report their study findings on the safety of omitting radiotherapy after breast-conserving surgery, sentinel node biopsy, and adjuvant endocrine therapy in older patients with early breast cancer and favorable histopathology at SABCS 2016.
Researchers investigated the potential of PID fluorescent nanoparticles, a novel detection technique to visualize and quantify protein in clinical samples, for quantifying HER2 protein expression in breast cancer, according to a study presented at SABCS 2016.
Robustness of dichotomous assessment is important when evaluating stromal features of ductal carcinoma in situ (DCIS), according to a study presented at SABCS 2016.
Research presented at 2016 SABCS showed whether RANKL inhibition could reduce the risk for developing breast cancer in BRCA1 mutation carriers.
Bi-allelic inactivation of BRCA1 and BRCA2 are frequent events in BRCA1 breast cancers and BRCA2 breast cancers, respectively, according to a study presented at SABCS 2016.
In this study presented at SABCS 2016, investigators determined the association between higher TIL levels and overall survival in patients with advanced HER2-positive breast cancer treated with docetaxel plus trastuzumab in combination with pertuzumab or placebo.
Researchers assessed the relationship between immune gene expression and genomic complexity in TNBC in a study presented at SABCS 2016.
Today at SABCS 2016 investigators presented results of the NRG Oncology/NSABP B-42, a double-blind phase 3 trial to determine whether extended treatment with letrozole would improve disease-free survival in certain women with HR-positive breast cancer.
At SABCS 2016, researchers presented study findings demonstrating whether neoadjuvant treatment, PARPi-7, BRCAness, and MP1/2 predict response to veliparib plus carboplatin therapy in patients with high-risk breast cancer.
A study using focus groups identifies barriers that impact the quality of survivorship care for Latina women with breast cancer.
Equivalent response rate for women with ERBB2-positive metastatic breast cancer receiving taxanes
The effects of a 2-treatment course of acupuncture on pain, nausea, and anxiety and ability to cope among women undergoing mastectomy was compared with usual care.
Perindopril, Bisoprolol Not Effective for Preventing Trastuzumab-mediated Left Ventricular Remodeling
Perindopril, an angiotensin-converting enzyme (ACE) inhibitor, and the beta blocker bisoprolol protected against trastuzumab-related declines.
Loss of bone density related to chemotherapy and adjuvant therapy for breast cancer can lead to debilitating hip and vertebral fractures. This discussion discusses the impact of resistance training for these patients.
An analysis of data from Danish women with early-stage breast cancer assessed women's risk of receiving nonguideline treatment for their disease if they had a prior diagnosis of depression or prior treatment with antidepressants.
The feasibility of an estradiol-releasing vaginal ring vs intravaginal testosterone cream for women with HR-positive stage I to III breast cancer using aromatase inhibitors who reported vaginal dryness, decreased libido, or dyspareunia is evaluated in a phase 2 study.
Investigators examined the extent to which hospital volume explains variations in diagnosis and treatment of breast cancer.
An analysis of data from women with stage I to III breast cancer investigated the potential association between protein intake and survival.
Economic Burden Related to Chemotherapy-related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System
[Breast Cancer: Targets and Therapy] This research evaluates costs related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care delivery system.
Study evaluates whether a web-based rehabilitation program can effectively improve pain, fatigue, strength, and quality of life for breast cancer survivors.
No greater risk of complications for older patients; benefited as much as younger breast cancer patients
Expression of this hormone receptor may indicate a less aggressive subtype of triple-negative breast cancer and better prognosis for patients with the disease.
A data analysis reveals the likelihood of older women with to ER-positive DCIS to initiate and adhere to adjuvant tamoxifen or aromatase inhibitors.
In this study, researchers assessed data on women who underwent breast cancer treatment to identify the factors associated with posttreatment imaging use.
The recurrence score assay stratifies early stage, estrogen receptor-positive breast cancer by recurrence risk. This study assessed how clinicians use the recurrence score to recommend adjuvant systemic therapy or patients' experiences with testing decision-making.
Researchers examined the long-term effects of a short-term culturally based dietary intervention on increasing the consumption of fruits and vegetables, decreasing fat, and changing biomarkers associated with recurrence in Hispanic breast cancer survivors.
Cancers that cause more readily noticeable physical changes can produce self-image challenges for patients. This discussion reviews what interventions can help validate patients' self-image concerns.
Researchers found wide variances in the cost of breast cancer chemotherapy, depending on the course of treatment selected.
Patients with breast cancer have more than 2 times the risk for developing a venous thromboembolism 5 years after diagnosis compared with the general population.
CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer
Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.
Expectations of Chemotherapy Side Effects Influence Patients' Experiences During Breast Cancer Treatment
Recent studies indicate that adverse side effects can result from factors unrelated to the pharmacologic agent, but rather from other factors.
Overall, 66.2 and 69.1 percent of women perceive high PCP engagement and communication
Primary prophylaxis with granulocyte colony-stimulating factor provided only a low-to-modest benefit in reducing neutropenia-related hospitalization in patients with breast cancer receiving low-to-intermediate risk chemotherapy regimens.
[Clinical Medicine Insights: Oncology] A case study of a 49-year-old premenopausal woman with metastatic invasive ductal breast carcinoma in the vertebral and iliac bones, which progressed with new metastases to her hips, thigh bones, and vertebrae.
For women receiving tamoxifen in the adjuvant setting for early stage breast cancer or as a preventive for high risk of breast cancer, the risk of developing endometrial pathology in those with negative uterine examination findings prior to treatment is very low.
Following the release of the Affordable Care Act (ACA) an increase in Hispanic women receiving breast cancer treatment and their related participation in clinical trials was observed.
Patients with early stage breast cancer who received breast-conserving surgery and were eligible for observation were more likely to undergo adjuvant radiotherapy in facilities performing APBI.
The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology have issued a joint consensus guideline update for the use of radiotherapy following mastectomy in patients with breast cancer.
Primary prophylaxis with G-CSF may modestly reduce neutropenia-related hospitalization in patients with breast cancer receiving docetaxel and cyclophosphamide or docetaxel, carboplatin, and trastuzumab.
Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
Bioimpedance spectroscopy (BIS) effectively assesses for subclinical breast cancer-related lymphedema in patients at risk, and accurately assess patients for response to treatment.
Inducing quiescent dormancy with conventional chemotherapy makes cancer cells more susceptible to immunotherapy, thereby minimizing potential for tumor recurrence.
Natural language processing (NLP) software correlated key characteristics expressed verbally in mammography reports with pathologic findings, providing an accurate indication for biopsy referral.
An experimental drug, AMPI-109, shows promise as an immunotherapy that sensitizes triple-negative breast cancer cells, enhancing the effectiveness of the drug.
African American survivors of breast cancer experience significant problem burden during the first 5 years after diagnosis and treatment.
A Systematic Review and Meta-analysis of Harmonic Technology Compared With Conventional Techniques in Mastectomy and Breast-conserving Surgery With Lymphadenectomy for Breast Cancer
[Breast Cancer: Targets and Therapy] This research compares Harmonic technology and conventional techniques for a range of clinical outcomes and complications in both mastectomy and BCS patients, including axillary lymph node dissection.
Greater negative beliefs regarding the challenges of their aromatase inhibitor treatment more likely to lead to nonadherence.
Skilled radiologists see abnormalities immediately, and researchers want to learn how they do it.
A novel sentinel lymph node (SLN) radiotracer, 99mTC-rituximab, demonstrated nearly 100% detection/success rate in SLN and metastasis in breast cancer.
The 70-gene signature test, in combination with standard clinical-pathologic criteria, may help clinicians decide whether patients with early stage breast cancer who are at high clinical risk require adjuvant chemotherapy.
Adolescent girls from BRCA1/2 mutation-positive and breast cancer families have high self-esteem but greater breast-cancer specific-distress.
Postmastectomy pain syndrome (PMPS) is a debilitating late effect of surgery and radiation therapy for breast cancer.
Negative patient expectations are associated with an increased risk of adverse events in patients with breast cancer undergoing endocrine therapy.
Estrogen receptor (ER)-positive breast cancers are often not a single tumor but a composite of related tumors, referred to as sub-clones.
Routine testing for hormone receptors in tissue obtained in a first needle biopsy for ductal carcinoma in situ (DCIS).
Change in tumor size at week 8 may predict overall survival during first-line therapy in patients with metastatic breast cancer.
Participation in exercise may reduce mortality compared with nonparticipation in patients with breast cancer.
Losing weight through diet or diet and exercise improves risk for cancer in overweight or obese postmenopausal women. Although exercise alone can help maintain weight loss, it is not as effective as diet and exercise.
Consensus guideline states that a 2 mm margin is enough to guard against recurrences while reducing need for additional operations for women with DCIS who undergo breast-conserving surgery.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|